Payment overview · 2025
General Payments
$875.99
42 reported records · 12 companies
Healthcare provider profile · identity verified
Nicholas R Lemming, MD
Allopathic & Osteopathic Physicians|Family Medicine · SEYMOUR, IN · NPI 1427033562
Verified facts
What the public records show
CMS Open Payments records show Nicholas R Lemming, MD received $875.99 in general payments during 2025 across 42 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 286 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 286 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 253 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 210 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 406 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $190.82 | 21.8% | 7 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $151.24 | 17.3% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $114.77 | 13.1% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $103.82 | 11.8% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $95.28 | 10.9% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $78.62 | 9.0% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $44.32 | 5.1% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $25.79 | 2.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.76 | 2.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.28 | 2.2% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $16.35 | 1.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.94 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $838.29 | 40 |
| Education | $37.70 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $151.24 | 6 | 2025 |
Source payment records
|
|||||
| BEVESPI AEROSPHERE Normalized: bevespi aerosphere |
Drug | AstraZeneca Pharmaceuticals LP | $126.99 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $114.77 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $113.11 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $110.43 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $86.66 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $48.05 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $34.31 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.57 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.57 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.17 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.17 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $25.79 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $15.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 111 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 286 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 253 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 210 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 74 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 178 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
101 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
111 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
286 | 53 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
178 | 56 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
286 | 53 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
253 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
69 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
210 | 39 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
74 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
406 | 76 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 814 | 229 |
| Levothyroxine Sodium | Levothyroxine Sodium | 748 | 163 |
| Amlodipine Besylate | Amlodipine Besylate | 726 | 193 |
| Pantoprazole Sodium | Pantoprazole Sodium | 669 | 172 |
| Lisinopril | Lisinopril | 634 | 167 |
| Gabapentin | Gabapentin | 618 | 164 |
| Montelukast Sodium | Montelukast Sodium | 559 | 167 |
| Metoprolol Succinate | Metoprolol Succinate | 549 | 145 |
| Losartan Potassium | Losartan Potassium | 542 | 147 |
| Omeprazole | Omeprazole | 503 | 126 |
| Furosemide | Furosemide | 490 | 141 |
| Prednisone | Prednisone | 460 | 293 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 435 | 125 |
| Hydrochlorothiazide | Hydrochlorothiazide | 428 | 100 |
| Eliquis | Apixaban | 406 | 76 |
| Meloxicam | Meloxicam | 383 | 95 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 378 | 92 |
| Metformin Hcl | Metformin Hcl | 357 | 90 |
| Metformin Hcl Er | Metformin Hcl | 338 | 95 |
| Potassium Chloride | Potassium Chloride | 331 | 87 |
| Pravastatin Sodium | Pravastatin Sodium | 322 | 80 |
| Jardiance | Empagliflozin | 286 | 53 |
| Trazodone Hcl | Trazodone Hcl | 282 | 68 |
| Bupropion Xl | Bupropion Hcl | 279 | 68 |
| Mounjaro | Tirzepatide | 253 | 48 |
| Buspirone Hcl | Buspirone Hcl | 248 | 67 |
| Escitalopram Oxalate | Escitalopram Oxalate | 240 | 64 |
| Mirtazapine | Mirtazapine | 233 | 71 |
| Clopidogrel | Clopidogrel Bisulfate | 232 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 231 | 95 |
| Tamsulosin Hcl | Tamsulosin Hcl | 229 | 67 |
| Tramadol Hcl | Tramadol Hcl | 221 | 59 |
| Alendronate Sodium | Alendronate Sodium | 219 | 57 |
| Famotidine | Famotidine | 218 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 212 | 60 |
| Ozempic | Semaglutide | 210 | 39 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 189 | 42 |
| Colestipol Hcl | Colestipol Hcl | 180 | 55 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 178 | 56 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 171 | 47 |
| Carvedilol | Carvedilol | 168 | 50 |
| Pioglitazone Hcl | Pioglitazone Hcl | 164 | 33 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 162 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 157 | 59 |
| Duloxetine Hcl | Duloxetine Hcl | 157 | 44 |
| Baclofen | Baclofen | 153 | 35 |
| Allopurinol | Allopurinol | 152 | 39 |
| Sertraline Hcl | Sertraline Hcl | 150 | 37 |
| Simvastatin | Simvastatin | 147 | 42 |
| Fluoxetine Hcl | Fluoxetine Hcl | 146 | 37 |
| Spironolactone | Spironolactone | 146 | 41 |
| Glimepiride | Glimepiride | 139 | 33 |
| Alprazolam | Alprazolam | 137 | 24 |
| Clonazepam | Clonazepam | 130 | 30 |
| Indapamide | Indapamide | 129 | 33 |
| Pregabalin | Pregabalin | 128 | 40 |
| Farxiga | Dapagliflozin Propanediol | 111 | 28 |
| Atenolol | Atenolol | 102 | 27 |
| Synthroid | Levothyroxine Sodium | 101 | 27 |
| Topiramate | Topiramate | 101 | 34 |
| Celecoxib | Celecoxib | 99 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 99 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | 17 |
| Xarelto | Rivaroxaban | 94 | 18 |
| Nortriptyline Hcl | Nortriptyline Hcl | 86 | 24 |
| Glipizide Er | Glipizide | 85 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 84 | 72 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 78 | 47 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 19 |
| Rybelsus | Semaglutide | 74 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 74 | 21 |
| Fluconazole | Fluconazole | 72 | 45 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 71 | 20 |
| Meclizine Hcl | Meclizine Hcl | 70 | 24 |
| Trulicity | Dulaglutide | 69 | 16 |
| Nystatin | Nystatin | 68 | 32 |
| Cefdinir | Cefdinir | 67 | 57 |
| Donepezil Hcl | Donepezil Hcl | 66 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 20 |
| Azithromycin | Azithromycin | 64 | 57 |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 32 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 63 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 63 | 52 |
| Lorazepam | Lorazepam | 63 | 20 |
| Cephalexin | Cephalexin | 62 | 41 |
| Ondansetron Hcl | Ondansetron Hcl | 61 | 34 |
| Klor-Con M20 | Potassium Chloride | 60 | 26 |
| Myrbetriq | Mirabegron | 60 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 59 | 16 |
| Dexlansoprazole Dr | Dexlansoprazole | 58 | suppressed |
| Memantine Hcl | Memantine Hcl | 57 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 15 |
| Warfarin Sodium | Warfarin Sodium | 56 | 13 |
| Clonidine Hcl | Clonidine Hcl | 55 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 20 |
| Finasteride | Finasteride | 53 | suppressed |
| Eszopiclone | Eszopiclone | 52 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 52 | 33 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 52 | 12 |
| Amoxicillin | Amoxicillin | 51 | 47 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | 24 |
| Sucralfate | Sucralfate | 49 | 30 |
| Estradiol | Estradiol | 48 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 27 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 46 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 44 | suppressed |
| Glipizide | Glipizide | 43 | suppressed |
| Ramipril | Ramipril | 43 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | suppressed |
| Ibuprofen | Ibuprofen | 39 | 18 |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Lovastatin | Lovastatin | 38 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 38 | suppressed |
| Ezetimibe | Ezetimibe | 37 | 14 |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 35 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 35 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 34 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 33 | suppressed |
| Acyclovir | Acyclovir | 32 | suppressed |
| Primidone | Primidone | 32 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 31 | 12 |
| Droplet Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Torsemide | Torsemide | 31 | 11 |
| Varenicline Tartrate | Varenicline Tartrate | 31 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | 13 |
| Azelastine Hcl | Azelastine Hcl | 29 | 13 |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 13 |
| Risperidone | Risperidone | 29 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 29 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 28 | 22 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 28 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 28 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 26 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 17 |
| Propranolol Hcl Er | Propranolol Hcl | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Dexamethasone | Dexamethasone | 25 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 25 | 12 |
| Rabeprazole Sodium | Rabeprazole Sodium | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | 11 |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | 15 |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 22 |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Belsomra | Suvorexant | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 22 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 21 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 16 |
| Colchicine | Colchicine | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Lubiprostone | Lubiprostone | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Constulose | Lactulose | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Roflumilast | Roflumilast | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 15 |
| Nabumetone | Nabumetone | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Phenytoin | Phenytoin | 14 | suppressed |
| Piroxicam | Piroxicam | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Dayvigo | Lemborexant | 13 | suppressed |
| Nortrel | Norethindrone-Ethin. Estradiol | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Famciclovir | Famciclovir | 11 | suppressed |
| Klayesta | Nystatin | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Welchol | Colesevelam Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $875.99 · 42 records | AstraZeneca Pharmaceuticals LP | BEVESPI AEROSPHERE, BREZTRI, CAPLYTA, FARXIGA, FREESTYLE LIBRE 3, INGREZZA, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Wegovy, XYOSTED, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error